On Tuesday, Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) was -3.14% drop from the session before settling in for the closing price of $469.97. A 52-week range for VRTX has been $377.85 – $519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 28.45% over the past five years. When this article was written, the company’s average yearly earnings per share was at 4175.27%. With a float of $256.19 million, this company’s outstanding shares have now reached $256.90 million.
Let’s look at the performance matrix of the company that is accounted for 5400 employees. In terms of profitability, gross margin is 86.1%, operating margin of -2.96%, and the pretax margin is 2.45%.
Vertex Pharmaceuticals, Inc (VRTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vertex Pharmaceuticals, Inc stocks. The insider ownership of Vertex Pharmaceuticals, Inc is 0.52%, while institutional ownership is 92.78%. The most recent insider transaction that took place on Feb 11 ’25, was worth 1,578,744. Before that another transaction happened on Feb 11 ’25, when Company’s Officer proposed sale 310 for $459.83, making the entire transaction worth $142,547.
Vertex Pharmaceuticals, Inc (VRTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 4175.27% per share during the next fiscal year.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
You can see what Vertex Pharmaceuticals, Inc (VRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.21, a number that is poised to hit 4.24 in the next quarter and is forecasted to reach 20.25 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) saw its 5-day average volume 1.42 million, a negative change from its year-to-date volume of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 54.31%. Additionally, its Average True Range was 12.52.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 54.47%, which indicates a significant increase from 45.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.65% in the past 14 days, which was higher than the 33.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $440.12, while its 200-day Moving Average is $461.68. Nevertheless, the first resistance level for the watch stands at $464.78 in the near term. At $474.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $480.48. If the price goes on to break the first support level at $449.08, it is likely to go to the next support level at $442.93. Assuming the price breaks the second support level, the third support level stands at $433.38.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
There are 257,529K outstanding shares of the company, which has a market capitalization of 117.23 billion. As of now, sales total 9,869 M while income totals 3,620 M. Its latest quarter income was 2,772 M while its last quarter net income were 1,045 M.
